share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  06/11 08:32
Moomoo AI 已提取核心訊息
On June 6, 2024, SeaStar Medical Holding Corporation, a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol ICU, reported significant financial transactions with an institutional investor known as Investor D. The company redeemed $0.7 million of the remaining outstanding convertible notes that were originally issued on December 11, 2023, along with accrued interest and make-whole amounts. The redemption was executed at 200% of the conversion amount as per the terms agreed upon. Concurrently, Investor D converted approximately $0.6 million of unpaid principal and $0.7 million of unpaid interest and make-whole amounts into 2,321,429 shares of common stock, which, due to a 25-for-1 reverse stock split effective from June 7, 2024, equates to 92,858 post-split shares. Following these transactions, there are no remaining outstanding Investor D convertible notes. However, Investor D retains warrants to purchase around 3,158,086 shares of SeaStar Medical's stock at a weighted-average exercise price of $0.55, which adjusts to $13.75 post-reverse split. The company's CEO, Eric Schlorff, signed off on the report.
On June 6, 2024, SeaStar Medical Holding Corporation, a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol ICU, reported significant financial transactions with an institutional investor known as Investor D. The company redeemed $0.7 million of the remaining outstanding convertible notes that were originally issued on December 11, 2023, along with accrued interest and make-whole amounts. The redemption was executed at 200% of the conversion amount as per the terms agreed upon. Concurrently, Investor D converted approximately $0.6 million of unpaid principal and $0.7 million of unpaid interest and make-whole amounts into 2,321,429 shares of common stock, which, due to a 25-for-1 reverse stock split effective from June 7, 2024, equates to 92,858 post-split shares. Following these transactions, there are no remaining outstanding Investor D convertible notes. However, Investor D retains warrants to purchase around 3,158,086 shares of SeaStar Medical's stock at a weighted-average exercise price of $0.55, which adjusts to $13.75 post-reverse split. The company's CEO, Eric Schlorff, signed off on the report.
海星醫療控股公司於2024年6月6日披露了與機構投資者D先生的顯著財務交易。這家在納斯達克股票交易市場上以ICU爲標的的特拉華州註冊公司已贖回了餘額爲70萬美元的可轉換債券，該債券最初是於2023年12月11日發行的，同時支付了應計利息以及整全份額，並按約定條款執行了以轉換金額2倍的價格贖回。同時，D先生將未償還的本金約60萬美元以及應計利息和整全份額約70萬美元轉換成了232萬1429股普通股，由於在2024年6月7日開始實施的25-1股票分割，這些股票將等同於92,858股拆股後股票。在這些交易後，D先生已不持有海星醫療控股公司未到期可轉換債券。但D先生保留了購買約3,158,086股海星醫療控股公司股票的權利，行權價格加權平均值爲0.55美元，拆股後調整爲13.75美元。該公司的首席執行官Eric Schlorff簽署了這份報告。
海星醫療控股公司於2024年6月6日披露了與機構投資者D先生的顯著財務交易。這家在納斯達克股票交易市場上以ICU爲標的的特拉華州註冊公司已贖回了餘額爲70萬美元的可轉換債券，該債券最初是於2023年12月11日發行的，同時支付了應計利息以及整全份額，並按約定條款執行了以轉換金額2倍的價格贖回。同時，D先生將未償還的本金約60萬美元以及應計利息和整全份額約70萬美元轉換成了232萬1429股普通股，由於在2024年6月7日開始實施的25-1股票分割，這些股票將等同於92,858股拆股後股票。在這些交易後，D先生已不持有海星醫療控股公司未到期可轉換債券。但D先生保留了購買約3,158,086股海星醫療控股公司股票的權利，行權價格加權平均值爲0.55美元，拆股後調整爲13.75美元。該公司的首席執行官Eric Schlorff簽署了這份報告。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息